We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · January 24, 2022

Combination Therapy With Pioglitazone/Exenatide Metformin and Hepatic Fibrosis and Steatosis Prevalence

Diabetes, Obesity & Metabolism

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Combination Therapy with Pioglitazone/Exenatide Metformin Reduces the Prevalence of Hepatic Fibrosis and Steatosis: The Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) Trial
Diabetes Obes Metab 2022 Jan 10;[EPub Ahead of Print], O Lavynenko, M Abdul-Ghani, M Alatrach, C Puckett, J Adams, S Abdelgani, N Alkhouri, C Triplitt, GD Clarke, JA Vasquez, J Li, E Cersosimo, A Gastaldelli, RA DeFronzo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading